KW 8232

Drug Profile

KW 8232

Latest Information Update: 26 Oct 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Indoles; Mesylates; Osteoporosis therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 26 Oct 2006 Discontinued - Preclinical for Postmenopausal osteoporosis in Japan (PO)
  • 12 Mar 2003 No development reported - Preclinical for Postmenopausal osteoporosis in Japan (PO)
  • 26 May 2001 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top